Katarzyna Pawińska-Wąsikowska
A5034596046- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Childhood Cancer Survivors' Quality of Life
- Ocular Oncology and Treatments
- Neuroblastoma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Brain Metastases and Treatment
- Hematopoietic Stem Cell Transplantation
- Head and Neck Surgical Oncology
- Chronic Lymphocytic Leukemia Research
- Neonatal Health and Biochemistry
- Retinoids in leukemia and cellular processes
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Autoimmune and Inflammatory Disorders Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- CAR-T cell therapy research
- Neuroendocrine Tumor Research Advances
- Sarcoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer-related Molecular Pathways
- Parvovirus B19 Infection Studies
- Immunodeficiency and Autoimmune Disorders
- Immune responses and vaccinations
Jagiellonian University
2012-2024
Uniwersytecki Szpital Dziecięcy
2010-2024
University School of Physical Education in Kraków
2021-2023
Abstract Acute lymphoblastic leukemia expressing the gamma delta T-cell receptor (γδ T-ALL) is a poorly understood disease. We studied 200 children with γδ T-ALL from 13 clinical study groups to understand and genetic features of this found age drivers were significantly associated outcome. diagnosed in under 3 years was extremely high-risk enriched for alterations that result both LMO2 activation STAG2 inactivation. Mechanistically, using patient samples isogenic cell lines, we show...
Despite the progress that has been made in recent decades treatment of pediatric acute leukemias, e.g., converting lymphoblastic leukemia (ALL) from a fatal to highly curable disease, 15-20% children still relapse. Blinatumomab, bispecific CD3/CD19 antibody construct, successfully used relapsed/refractory r/r B-cell precursor ALL (BCP-ALL) as bridge hematopoietic stem cell transplantation (HSCT). We retrospectively assessed efficacy and toxicity blinatumomab 13 with BCP-ALL. Between 2017...
Prognosis in children with refractory and relapsed high-risk neuroblastoma is poor. Only a minority of patients obtain remission when treated second-line chemotherapy regimens. Chemotherapy combined anti-GD2 antibodies has previously been shown to increase response survival rates. We retrospectively analyzed cohort 25 or who were irinotecan/temozolomide combination the antibody dinutuximab beta. The therapy resulted an objective rate 64%, 32% achieving complete response. Response treatment...
Background: Acinetobacter, significantly A.baumannii, are becoming a great threat to hospitalized patients due increasing antibiotic resistance. The aim of this study was describe the epidemiology, clinical characteristic, antimicrobial susceptibility pattern and outcome Acinetobacter infections in pediatric cancer HSCT recipients Poland. Methods: total 125 episodes species were reported pa-tients < 18 years treated Polish hematology oncology centers over pe-riod from 2012 2023....
Background/aim: The role of immune checkpoint inhibitors (ICIs; anti-PD1) in the treatment childhood cancers is still evolving. aim this nationwide retrospective study was to assess safety and effectiveness ICIs used a group 42 patients, with median age 13.6 years, various types advanced malignancies treated pediatric oncology centers Poland between 2015 2023. Results: indications for anti-PD1 were as follows: Hodgkin lymphoma (11); malignant skin melanoma (9); neuroblastoma (8); other (14)....
Abstract Introduction Advanced intraocular retinoblastoma can be cured by enucleation, but spread of cells beyond the natural limits eye is related to a high mortality. Adjuvant therapy after enucleation has been shown prevent metastasis in children with risk factors for extraocular retinoblastoma. However, histological criteria and adjuvant treatment regimens vary there no unifying consensus on optimal choice treatment. Method Data guidelines European referral centres were collected an...
Background/Aim: Nivolumab is an immune checkpoint inhibitor with high antitumor activity in selected neoplasms. The aim of the study was to evaluate efficacy and safety nivolumab pediatric patients various types highly malignant advanced tumors. Patients Methods: Ten a median age 15.1 years were included study. indications for treatment were: skin melanoma (n=5), brain tumor (n=2), (n=1), Hodgkin lymphoma (n=1) soft tissue sarcoma (n=1). Results: Complete disease remission observed 4...
Background: From 1983, standardized therapeutic protocols for pediatric acute myeloid leukemia (AML) based on the BFM group experience were introduced in Poland. We retrospectively analyzed results of AML treatment Poland from 1983 to 2019 (excluding promyelocytic, therapy-related, biphenotypic, and Down syndrome AML). Methods: The study included 899 children suffering treated with following: AML-PPPLBC 83 (1983–1993, n = 187), AML-PPGLBC 94 (1994–1997, 74), 98 (1998–2004, 151), AML-BFM 2004...
Since 1983 four consecutive unified regimens: acute myeloid leukemia-Polish pediatric leukemia/lymphoma study group (AML-PPLLSG) 83, AML-PPLLSG 94, 98 and AML-BFM 2004 Interim, for AML have been conducted by the Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG). In this paper, we review successive studies on basis of leukemia-Berlin-Frankfurt-Munster (AML-BFM) protocol, in which a stepwise improvement treatment outcome was observed. Treatment results last protocol Interim are presented...
Abstract Minimal residual disease (MRD) enables reliable assessment of risk in acute lymphoblastic leukemia (ALL). However, little is known on association between MRD status and germline genetic variation. We examined 159 Caucasian (Slavic) patients with pediatric ALL, treated according to ALL-IC-BFM 2002/2009 protocols, search for 23 polymorphisms at day 15, 33 week 12, adjustment MRD-associated clinical covariates. Three variants were significantly associated MRD: rs1544410 VDR...
Acute P./myeloid leukemia post cytotoxic therapy (AML-pCT) is rare complication of cancer treatment in childhood. The objective the study was to identify clinical characteristics and provide an analysis outcomes pediatric AML-pCT. We retrospectively analyzed data 40 children with AML-pCT, treated from 2005 2020 within Polish Pediatric Leukemia Lymphoma Study Group. most common primary malignancies were acute lymphoblastic (32.5%) brain tumors (20%). median latency period 2.9 years (range:...
Whilst the survival rates of childhood acute lymphoblastic leukemia (ALL) have increased remarkably over last decades, therapy resistance and toxicity are still major causes treatment failure. It was shown that overexpression heme oxygenase-1 (HO-1) promotes proliferation chemoresistance cancer cells. In humans, HO-1 gene (HMOX1) expression is modulated by two polymorphisms in promoter region: (GT)n-length polymorphism single-nucleotide (SNP) A(−413)T, with short GT repeat sequences 413-A...
Background: The reports of studies that compare the survival adolescents and young adults with younger children acute myeloid leukemia (AML) are contradictory. Patients Methods: We retrospectively analyzed 220 AML patients aged 0–18 years treated in pediatric oncologic centers Poland from 2015 to 2022. evaluated group included 31 infants (below 1 year), 91 (1–9.9 years), 59 older (10–14.9 39 (15–18 years). Results: A 5-year overall for was not significantly inferior compared (74.3 ± 7.6% vs....
Infections remain the leading cause of mortality among neutropenic patients with haematologic malignancies, making effective infection management crucial. Achieving a sufficient neutrophil count is essential for elimination pathogens. Granulocyte concentrate (GC) can be treatment option severe infections. This study aimed to evaluate efficacy, safety, and impact on survival GC transfusions in children infections treated over past 13 years single centre.
Introduction: Peritoneal metastases occur in cancers that spread to the peritoneal cavity and indicate advanced stage of disease. In children they are mainly seen sarcomas, Gastrointestinal Stromal Tumors primary disseminated ovarian tumors. Inflammatory Myofibroblastic Tumor (IMT) is a very rare lesion, characterized by an unpredictable clinical course. The absorption chemotherapeutic agents through peritoneal-plasma barrier (PPB) minimized, thus HIPEC procedure limits systemic exposure...
Dinutuximab beta is approved for the maintenance treatment of patients with high-risk neuroblastoma (HR-NB), including relapsed/refractory (R/R) disease. However, data on its use in real-world clinical practice limited. We retrospectively reviewed records 54 HR-NB who received therapy dinutuximab first-line (37 patients) or R/R settings (17 at three centers Poland. Of 37 treatment, twenty-eight had a complete response, two partial progressive disease, and four relapsed end treatment. The...
The association between acute lymphoblastic leukemia (ALL), non-Langerhans cell histiocytosis (non-LCH), and hemophagocytic lymphohistiocytosis (HLH), to the best of our knowledge, has not been published date. Juvenile xanthogranuloma (JXG), as a type non-LCH, is usually benign disease limited skin. Systemic involvement rarely reported. present case report describes 15-year-old boy diagnosed with disseminated JXG involving skin bone marrow concurrent severe symptoms HLH during ALL therapy....
Background: Children with Down syndrome (DS) have increased risk of myeloid leukemia, but specific treatment protocols ensure excellent outcome. The aim the study was retrospective analysis results and genetic characteristics leukemia (ML-DS) in Poland from 2005 to 2019. Methods: All 54 patients ML-DS registered Polish Pediatric Leukemia Lymphoma Study Group analyzed period were enrolled study. There 34 children treated AML-BFM 2004 Interim protocol (group I) 20 2006 II). In first there...
11q23/MLL rearrangements are frequently detected in pediatric acute myeloid leukemia. The analysis of their clinical significance is difficult due to the multitude translocation fusion partners and low frequency. presence t(10;11)(p12;q23) was previously identified AML. It considered as second most common 11q23/MLL-rearranged (present KMT2A) AML, after t(9;11)(p22;q23). above an unfavorable prognostic factor. Since June 2015 Polish Pediatric Leukemia/Lymphoma Study Group has applied...
Background: The FMS-like tyrosine kinase 3 (FLT3) gene mutated in 10–15% of pediatric acute myeloid leukemia (AML) is associated with an inferior outcome. aim the study was to analyze outcome and characteristics FLT3-ITD-positive AML. Methods: We retrospectively analyzed nationwide AML database from between 2005 2022. FLT3-ITD found 54/497 (10.7%) patients available analysis. Three consecutive treatment protocols were used (AML-BFM 2004 Interim, AML-BFM 2012 Registry, 2019 recommendations)....
Background Gemtuzumab ozogamicin (GO), one of the first targeted drugs used in oncology, consists an anti-cluster differentiation 33 (CD33) monoclonal antibody bound to a derivative cytotoxic calicheamicin. After drug withdrawn 2010 due significantly higher rate early deaths, GO regained approval 2017 for treatment newly diagnosed, refractory, or relapsed acute myeloid leukemia (AML) adults and children over 15 years age. The objective study was retrospective analysis clinical...